Disclosed is a lyophilized preparation of recombinant factor VIII used
as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant
factor VIII is prepared by performing lyophilization using a mixture comprising
6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic
acid as a stabilizer for stabilizing the recombinant factor VIII which exhibits
an unstable activity during lyophilization, rather than using human blood derived albumin.
